Lena Biosciences

Lena Biosciences is a biotechnology company that develops advanced 3D cell culture platforms and organ-on-a-chip systems for drug discovery and preclinical testing applications. Their technology enables the creation of physiologically relevant in vitro models that mimic the human body's microenvironment more accurately compared to traditional 2D cell cultures or animal models.

Lena Biosciences' flagship product is a 3D perfused cell culture platform that incorporates a breathable hemoglobin analogue to enhance and prolong the viability and functionality of primary human cells, such as hepatocytes. This innovative approach allows for more accurate modeling of human physiology and disease states, facilitating improved preclinical evaluation of drug candidates.

Furthermore, the company offers an organ-on-a-chip platform that replicates the complex microenvironment of human tissues and organs. This technology facilitates the study of drug efficacy, toxicity, and disease mechanisms in a controlled, high-throughput manner. Lena Biosciences' products have been validated for applications in various therapeutic areas, including breast cancer, where their 3D perfused cell culture platform has demonstrated its utility in humanized preclinical drug testing using established cell lines and patient-derived tissues.